FiercePharma17d
In FDA adcomm, Lexicon gets another thumbs down for type 1 diabetes hopeful Zynquista
Despite its unique ability to block sodium-glucose linked transporter 2 (SGLT2) in the kidneys and SGLT1 in the intestines, Lexicon’s Zynquista (sotagliflozin) has had difficulty negotiating ...
Nasdaq17d
FDA Panel Votes Against Lexicon's NDA For Zynquista In Type 1 Diabetes And Chronic Kidney Disease
(RTTNews) - Lexicon Pharmaceuticals Inc. (LXRX) announced that the U.S. Food and Drug Administration's Advisory Committee voted against the company's New Drug Application (NDA) for Zynquista ...
Reuters18d
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes
Oct 31 (Reuters) - Independent advisers to the U.S. Food and Drug Administration on Thursday voted against recommending Lexicon Pharmaceuticals' (LXRX.O), opens new tab add-on treatment to insulin ...
Business Insider19d
Optimistic Buy Rating for Lexicon Pharmaceuticals Due to Positive Outlook on Sotagliflozin’s FDA Review
Joseph Pantginis has given his Buy rating due to a combination of factors surrounding Lexicon Pharmaceuticals’ sotagliflozin, which is under review by the FDA as an adjunct therapy for Type 1 ...
Cambridge University Press27d
Apples, tomatoes, and health: comparison of structural characteristics of the L1 and L2 mental lexicons
María Pilar Agustín-Llach [Opens in a new window] and The present study delves into the structure and lexical organization of L1 and L2 mental lexicons. Indirect access to the mental lexicon is ...
Business Insider28d
Lexicon Pharmaceuticals: Strategic Advancements and Growth Potential Highlighted by Exclusive Licensing Deal and Undervalued Pipeline
Roanna Ruiz has given her Buy rating due to a combination of factors that highlight Lexicon Pharmaceuticals’ strategic advancements and potential for value growth. One significant reason is the ...